Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

Elias Jabbour; Sameer A. Parikh; Hagop Kantarjian; Jorge Cortes

doi:10.1016/j.hoc.2011.09.004

Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

Elias Jabbour, Sameer A. Parikh, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journal › Review article › peer-review

48 Scopus citations

Abstract

Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

Original language	English (US)
Pages (from-to)	981-995
Number of pages	15
Journal	Hematology/Oncology Clinics of North America
Volume	25
Issue number	5
DOIs	https://doi.org/10.1016/j.hoc.2011.09.004
State	Published - Oct 2011
Externally published	Yes

Keywords

Homoharringtonine
Multikinase inhibitors
Mutation screening
Myeloproliferative disorders
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2011.09.004

Cite this

@article{5a9527e8cee84a5d802e032ae8ac06a2,

title = "Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment",

abstract = "Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.",

keywords = "Homoharringtonine, Multikinase inhibitors, Mutation screening, Myeloproliferative disorders, Tyrosine kinase inhibitors",

author = "Elias Jabbour and Parikh, {Sameer A.} and Hagop Kantarjian and Jorge Cortes",

year = "2011",

month = oct,

doi = "10.1016/j.hoc.2011.09.004",

language = "English (US)",

volume = "25",

pages = "981--995",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Chronic Myeloid Leukemia

T2 - Mechanisms of Resistance and Treatment

AU - Jabbour, Elias

AU - Parikh, Sameer A.

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2011/10

Y1 - 2011/10

N2 - Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

AB - Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

KW - Homoharringtonine

KW - Multikinase inhibitors

KW - Mutation screening

KW - Myeloproliferative disorders

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=80755159112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755159112&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2011.09.004

DO - 10.1016/j.hoc.2011.09.004

M3 - Review article

C2 - 22054730

AN - SCOPUS:80755159112

SN - 0889-8588

VL - 25

SP - 981

EP - 995

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 5

ER -

Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this